Gcg-XTEN: An Improved Glucagon Capable of Preventing Hypoglycemia without Increasing Baseline Blood Glucose

OBJECTIVE: While the majority of current diabetes treatments focus on reducing blood glucose levels, hypoglycemia represents a significant risk associated with insulin treatment. Glucagon plays a major regulatory role in controlling hypoglycemia in vivo, but its short half-life and hyperglycemic eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Geething, Nathan C., To, Wayne, Spink, Benjamin J., Scholle, Michael D., Wang, Chia-wei, Yin, Yong, Yao, Yi, Schellenberger, Volker, Cleland, Jeffrey L., Stemmer, Willem P. C., Silverman, Joshua
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2854692/
https://www.ncbi.nlm.nih.gov/pubmed/20418955
http://dx.doi.org/10.1371/journal.pone.0010175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2854692/
https://www.ncbi.nlm.nih.gov/pubmed/20418955
http://dx.doi.org/10.1371/journal.pone.0010175

Ejemplares similares